Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avapritinib in GIST and other solid tumors
NCT02508532Phase 1Completed
- Sponsor
- Blueprint Medicines
- Start
- Aug 2015
- Primary completion
- Mar 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 10
01
Overview
Phase 1, open-label trial of avapritinib in gastrointestinal stromal tumor (GIST) and solid tumor (9 arms), sponsored by Blueprint Medicines. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 2 more. Started Aug 2015; status: completed.
02
Drugs
avapritinib
03
Conditions
gastrointestinal stromal tumor (GIST)solid tumor
Beyond the preview
Go deeper on NCT02508532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02508532.